

Developing an *in silico* minimum inhibitory concentration panel test for *Klebsiella pneumoniae*

Supplemental Information

Marcus Nguyen^{1,2,3}, Thomas Brettin^{2,3}, S. Wesley Long^{4,5}, James M. Musser^{4,5}, Randall J. Olsen^{4,5}, Robert Olson^{2,3}, Maulik Shukla^{2,3}, Rick L. Stevens^{2,3,7}, Fangfang Xia^{2,3}, Hyunseung Yoo^{2,3}, James J. Davis^{2,3,*}

¹Northern Illinois University, Computation Science, DeKalb, IL, 60115, USA

²University of Chicago, Computation Institute, Chicago, IL, 60637, USA

³Argonne National Laboratory, Computing Environment and Life Sciences, Argonne, IL, 60439, USA

⁴Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas, 77030, USA

⁵Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, 10065, USA

⁷University of Chicago, Department of Computer Science, Chicago, IL, 60439, USA

*corresponding author jjdavis@anl.gov

Table S1. A comparison of raw accuracies and accuracies within ± 1 two-fold dilution step of the actual MIC for the XGBoost model

| Antibiotic | Samples | Raw Accuracy ^a | Raw Accuracy ^a 95% C.I. ^b | Within 1 two-fold Accuracy ^c | Within 1 two-fold ^b 95% C.I. ^b |
|-------------------------------|---------|---------------------------|--|---|--|
| All | 32705 | 0.69 | 0.68, 0.69 | 0.92 | 0.92, 0.92 |
| Amikacin | 1667 | 0.69 | 0.67, 0.71 | 0.97 | 0.96, 0.98 |
| Ampicillin | 1666 | 0.95 | 0.94, 0.96 | 1.00 | 0.99, 1.00 |
| Ampicillin/Sulbactam | 1664 | 0.88 | 0.86, 0.90 | 0.99 | 0.99, 1.00 |
| Aztreonam | 1644 | 0.62 | 0.6, 0.65 | 0.89 | 0.89, 0.90 |
| Cefazolin | 1667 | 0.85 | 0.84, 0.86 | 0.96 | 0.95, 0.96 |
| Cefepime | 1571 | 0.19 | 0.16, 0.22 | 0.61 | 0.58, 0.64 |
| Cefoxitin | 1645 | 0.40 | 0.37, 0.43 | 0.90 | 0.89, 0.91 |
| Ceftazidime | 1667 | 0.73 | 0.71, 0.76 | 0.92 | 0.91, 0.93 |
| Ceftriaxone | 1667 | 0.73 | 0.71, 0.75 | 0.89 | 0.87, 0.90 |
| Cefuroxime sodium | 1575 | 0.94 | 0.93, 0.95 | 0.99 | 0.99, 1.00 |
| Ciprofloxacin | 1664 | 0.87 | 0.85, 0.89 | 0.98 | 0.97, 0.98 |
| Gentamicin | 1667 | 0.65 | 0.62, 0.68 | 0.95 | 0.93, 0.96 |
| Imipenem | 1666 | 0.70 | 0.68, 0.71 | 0.94 | 0.93, 0.95 |
| Levofloxacin | 1666 | 0.82 | 0.80, 0.83 | 0.97 | 0.96, 0.97 |
| Meropenem | 1660 | 0.69 | 0.66, 0.71 | 0.93 | 0.91, 0.95 |
| Nitrofurantoin | 895 | 0.78 | 0.75, 0.82 | 0.96 | 0.95, 0.97 |
| Piperacillin/Tazobactam | 1662 | 0.46 | 0.43, 0.49 | 0.78 | 0.77, 0.79 |
| Tetracycline | 1667 | 0.50 | 0.48, 0.53 | 0.89 | 0.87, 0.90 |
| Tobramycin | 1666 | 0.61 | 0.57, 0.64 | 0.95 | 0.94, 0.96 |
| Trimethoprim/Sulfamethoxazole | 1667 | 0.74 | 0.72, 0.76 | 0.95 | 0.94, 0.96 |

^a Average raw accuracy; raw accuracy is defined as predicting the actual MIC.

^b 95% confidence interval.

^c Average within ± 1 two-fold dilution accuracy.

Table S2. The within 1-tier accuracies for all antibiotic-MIC combinations.

| Antibiotic | MIC | Samples | Accuracy ^a | 95% C.I. ^b |
|----------------------|-------|---------|-----------------------|-----------------------|
| All | 0.02 | 1 | 0.00 | <i>nan, nan</i> |
| All | 0.03 | 1 | 0.00 | <i>nan, nan</i> |
| All | 0.09 | 1 | 0.00 | <i>nan, nan</i> |
| All | 0.13 | 282 | 0.92 | 0.86, 0.97 |
| All | 0.25 | 120 | 0.91 | 0.85, 0.97 |
| All | 0.38 | 1 | 0.00 | <i>nan, nan</i> |
| All | 0.5 | 784 | 0.72 | 0.69, 0.75 |
| All | 1.0 | 3118 | 0.84 | 0.83, 0.85 |
| All | 2.0 | 1775 | 0.80 | 0.78, 0.81 |
| All | 4.0 | 4459 | 0.93 | 0.92, 0.94 |
| All | 6.0 | 2 | 0.00 | 0.00, 0.00 |
| All | 8.0 | 3737 | 0.95 | 0.95, 0.96 |
| All | 11.0 | 2 | 1.00 | 1.00, 1.00 |
| All | 12.0 | 2 | 0.50 | -5.85, 6.85 |
| All | 14.0 | 2 | 0.50 | -5.85, 6.85 |
| All | 16.0 | 3896 | 0.92 | 0.91, 0.92 |
| All | 17.0 | 4 | 1.00 | 1.00, 1.00 |
| All | 18.0 | 11 | 0.65 | 0.31, 0.99 |
| All | 19.0 | 12 | 1.00 | 1.00, 1.00 |
| All | 20.0 | 15 | 1.00 | 1.00, 1.00 |
| All | 21.0 | 4 | 1.00 | 1.00, 1.00 |
| All | 23.0 | 1 | 1.00 | <i>nan, nan</i> |
| All | 32.0 | 10802 | 0.96 | 0.96, 0.96 |
| All | 50.0 | 5 | 0.20 | -0.36, 0.76 |
| All | 64.0 | 1834 | 0.94 | 0.93, 0.96 |
| All | 128.0 | 1833 | 0.91 | 0.89, 0.93 |
| All | 512.0 | 1 | 0.00 | <i>nan, nan</i> |
| Amikacin | 4.0 | 155 | 0.94 | 0.89, 0.99 |
| Amikacin | 8.0 | 1058 | 0.99 | 0.99, 1.00 |
| Amikacin | 16.0 | 107 | 1.00 | 1.00, 1.00 |
| Amikacin | 32.0 | 244 | 0.98 | 0.96, 1.00 |
| Amikacin | 64.0 | 103 | 0.70 | 0.64, 0.76 |
| Ampicillin | 2.0 | 1 | 0.00 | <i>nan, nan</i> |
| Ampicillin | 4.0 | 1 | 0.00 | <i>nan, nan</i> |
| Ampicillin | 8.0 | 2 | 1.00 | 1.00, 1.00 |
| Ampicillin | 16.0 | 27 | 1.00 | 1.00, 1.00 |
| Ampicillin | 32.0 | 1635 | 1.00 | 1.00, 1.00 |
| Ampicillin/Sulbactam | 2.0 | 3 | 0.33 | -1.10, 1.77 |
| Ampicillin/Sulbactam | 4.0 | 10 | 0.90 | 0.67, 1.13 |
| Ampicillin/Sulbactam | 8.0 | 77 | 0.96 | 0.90, 1.02 |
| Ampicillin/Sulbactam | 16.0 | 119 | 1.00 | 1.00, 1.00 |
| Ampicillin/Sulbactam | 32.0 | 1455 | 1.00 | 0.99, 1.00 |

| Antibiotic | MIC | Samples | Accuracy^a | 95% C.I.^b |
|-------------------|------------|----------------|-----------------------------|-----------------------------|
| Aztreonam | 1.0 | 81 | 0.79 | 0.69, 0.88 |
| Aztreonam | 2.0 | 99 | 0.12 | 0.04, 0.20 |
| Aztreonam | 4.0 | 36 | 0.08 | -0.01, 0.18 |
| Aztreonam | 8.0 | 21 | 0.67 | 0.43, 0.91 |
| Aztreonam | 16.0 | 92 | 1.00 | 1.00, 1.00 |
| Aztreonam | 32.0 | 1315 | 0.98 | 0.97, 0.98 |
| Cefazolin | 1.0 | 42 | 0.24 | 0.10, 0.39 |
| Cefazolin | 2.0 | 26 | 0.73 | 0.49, 0.97 |
| Cefazolin | 4.0 | 11 | 0.25 | -0.05, 0.55 |
| Cefazolin | 8.0 | 7 | 0.86 | 0.51, 1.21 |
| Cefazolin | 16.0 | 11 | 0.65 | 0.31, 0.99 |
| Cefazolin | 32.0 | 1478 | 1.00 | 1.00, 1.00 |
| Cefazolin | 64.0 | 92 | 0.80 | 0.67, 0.94 |
| Cefepime | 0.5 | 84 | 0.84 | 0.76, 0.92 |
| Cefepime | 1.0 | 307 | 0.08 | 0.05, 0.11 |
| Cefepime | 2.0 | 27 | 0.50 | 0.22, 0.78 |
| Cefepime | 4.0 | 119 | 0.84 | 0.78, 0.90 |
| Cefepime | 8.0 | 71 | 0.97 | 0.93, 1.01 |
| Cefepime | 16.0 | 173 | 0.94 | 0.89, 0.99 |
| Cefepime | 32.0 | 790 | 0.65 | 0.61, 0.70 |
| Cefoxitin | 4.0 | 423 | 0.80 | 0.77, 0.83 |
| Cefoxitin | 8.0 | 244 | 0.97 | 0.95, 1.00 |
| Cefoxitin | 16.0 | 150 | 0.97 | 0.94, 0.99 |
| Cefoxitin | 32.0 | 828 | 0.92 | 0.91, 0.94 |
| Ceftazidime | 0.5 | 86 | 0.40 | 0.28, 0.51 |
| Ceftazidime | 1.0 | 28 | 0.03 | -0.04, 0.11 |
| Ceftazidime | 2.0 | 10 | 0.30 | -0.05, 0.65 |
| Ceftazidime | 4.0 | 12 | 0.65 | 0.31, 0.99 |
| Ceftazidime | 8.0 | 43 | 0.84 | 0.73, 0.95 |
| Ceftazidime | 16.0 | 103 | 0.97 | 0.94, 1.00 |
| Ceftazidime | 32.0 | 1385 | 0.97 | 0.96, 0.98 |
| Ceftriaxone | 0.5 | 80 | 0.17 | 0.08, 0.27 |
| Ceftriaxone | 2.0 | 59 | 0.12 | 0.04, 0.20 |
| Ceftriaxone | 4.0 | 9 | 0.56 | 0.15, 0.96 |
| Ceftriaxone | 8.0 | 5 | 0.40 | -0.28, 1.08 |
| Ceftriaxone | 16.0 | 29 | 0.82 | 0.63, 1.00 |
| Ceftriaxone | 32.0 | 53 | 0.85 | 0.75, 0.96 |
| Ceftriaxone | 64.0 | 1432 | 0.96 | 0.96, 0.97 |
| Cefuroxime sodium | 4.0 | 75 | 0.91 | 0.86, 0.95 |
| Cefuroxime sodium | 8.0 | 16 | 0.95 | 0.84, 1.06 |
| Cefuroxime sodium | 16.0 | 15 | 0.95 | 0.84, 1.06 |
| Cefuroxime sodium | 32.0 | 1469 | 1.00 | 1.00, 1.00 |
| Ciprofloxacin | 0.5 | 158 | 0.80 | 0.73, 0.86 |
| Ciprofloxacin | 1.0 | 43 | 0.97 | 0.92, 1.03 |
| Ciprofloxacin | 2.0 | 39 | 1.00 | 1.00, 1.00 |
| Ciprofloxacin | 4.0 | 1424 | 1.00 | 0.99, 1.00 |

| Antibiotic | MIC | Samples | Accuracy^a | 95% C.I.^b |
|-------------------------|------------|----------------|-----------------------------|-----------------------------|
| Gentamicin | 0.5 | 13 | 0.65 | 0.36, 0.94 |
| Gentamicin | 1.0 | 94 | 0.90 | 0.85, 0.94 |
| Gentamicin | 2.0 | 645 | 0.97 | 0.95, 0.98 |
| Gentamicin | 4.0 | 174 | 0.99 | 0.97, 1.01 |
| Gentamicin | 8.0 | 58 | 0.91 | 0.85, 0.98 |
| Gentamicin | 16.0 | 683 | 0.93 | 0.92, 0.94 |
| Imipenem | 0.25 | 111 | 0.90 | 0.83, 0.97 |
| Imipenem | 0.5 | 38 | 0.94 | 0.85, 1.03 |
| Imipenem | 1.0 | 1011 | 0.96 | 0.95, 0.98 |
| Imipenem | 2.0 | 28 | 0.60 | 0.38, 0.82 |
| Imipenem | 4.0 | 37 | 0.84 | 0.69, 1.00 |
| Imipenem | 6.0 | 1 | 0.00 | nan, nan |
| Imipenem | 8.0 | 107 | 0.94 | 0.87, 1.02 |
| Imipenem | 16.0 | 333 | 0.92 | 0.88, 0.95 |
| Levofloxacin | 1.0 | 331 | 0.90 | 0.87, 0.93 |
| Levofloxacin | 2.0 | 18 | 0.80 | 0.55, 1.05 |
| Levofloxacin | 4.0 | 30 | 1.00 | 1.00, 1.00 |
| Levofloxacin | 8.0 | 1287 | 0.98 | 0.97, 0.99 |
| Meropenem | 0.02 | 1 | 0.00 | nan, nan |
| Meropenem | 0.03 | 1 | 0.00 | nan, nan |
| Meropenem | 0.09 | 1 | 0.00 | nan, nan |
| Meropenem | 0.13 | 147 | 0.92 | 0.86, 0.98 |
| Meropenem | 0.25 | 1 | 1.00 | nan, nan |
| Meropenem | 0.38 | 1 | 0.00 | nan, nan |
| Meropenem | 1.0 | 982 | 0.97 | 0.96, 0.98 |
| Meropenem | 2.0 | 45 | 0.60 | 0.50, 0.71 |
| Meropenem | 4.0 | 64 | 0.78 | 0.65, 0.90 |
| Meropenem | 6.0 | 1 | 0.00 | nan, nan |
| Meropenem | 8.0 | 50 | 0.92 | 0.85, 0.99 |
| Meropenem | 12.0 | 2 | 0.50 | -5.85, 6.85 |
| Meropenem | 16.0 | 364 | 0.90 | 0.85, 0.95 |
| Nitrofurantoin | 16.0 | 17 | 0.25 | -0.00, 0.50 |
| Nitrofurantoin | 32.0 | 38 | 0.79 | 0.65, 0.94 |
| Nitrofurantoin | 64.0 | 121 | 1.00 | 1.00, 1.00 |
| Nitrofurantoin | 128.0 | 719 | 0.98 | 0.97, 0.99 |
| Piperacillin/Tazobactam | 2.0 | 25 | 0.45 | 0.37, 0.53 |
| Piperacillin/Tazobactam | 4.0 | 130 | 0.45 | 0.41, 0.50 |
| Piperacillin/Tazobactam | 8.0 | 117 | 0.28 | 0.18, 0.39 |
| Piperacillin/Tazobactam | 16.0 | 160 | 0.68 | 0.59, 0.77 |
| Piperacillin/Tazobactam | 32.0 | 106 | 0.97 | 0.94, 1.00 |
| Piperacillin/Tazobactam | 64.0 | 76 | 0.96 | 0.90, 1.02 |
| Piperacillin/Tazobactam | 128.0 | 1048 | 0.87 | 0.84, 0.89 |
| Tetracycline | 1.0 | 51 | 0.82 | 0.78, 0.87 |
| Tetracycline | 2.0 | 214 | 0.61 | 0.54, 0.69 |
| Tetracycline | 4.0 | 474 | 0.99 | 0.98, 1.00 |
| Tetracycline | 8.0 | 150 | 0.99 | 0.98, 1.01 |
| Tetracycline | 16.0 | 778 | 0.89 | 0.87, 0.90 |

| Antibiotic | MIC | Samples | Accuracy^a | 95% C.I.^b |
|-------------------------------|------------|----------------|-----------------------------|-----------------------------|
| Tobramycin | 0.5 | 4 | 0.00 | 0.00,0.00 |
| Tobramycin | 1.0 | 91 | 0.91 | 0.86,0.96 |
| Tobramycin | 2.0 | 471 | 0.93 | 0.90,0.96 |
| Tobramycin | 4.0 | 23 | 0.90 | 0.75,1.05 |
| Tobramycin | 8.0 | 354 | 0.99 | 0.97,1.00 |
| Tobramycin | 16.0 | 723 | 0.96 | 0.94,0.98 |
| Trimethoprim/Sulfamethoxazole | 0.5 | 316 | 0.85 | 0.80,0.91 |
| Trimethoprim/Sulfamethoxazole | 1.0 | 54 | 0.83 | 0.69,0.97 |
| Trimethoprim/Sulfamethoxazole | 2.0 | 46 | 0.98 | 0.93,1.03 |
| Trimethoprim/Sulfamethoxazole | 4.0 | 1251 | 0.98 | 0.97,0.99 |

^a Average within ± 1 two-fold dilution accuracy.

^b 95% confidence interval.

Table S4. The top three PATRIC functions that are most highly correlated with the laboratory tested MICs for each antibiotic, and the corresponding PCCs based on MICs that are predicted by the model.

| Antibiotic | PATRIC Function | PCC Actual MIC | PCC Predicted MIC |
|----------------------|---|----------------|-------------------|
| Amikacin | IncI1 plasmid conjugative transfer prepilin PilS | 0.577 | 0.478 |
| | type III restriction enzyme, res subunit | 0.573 | 0.025 |
| | integral membrane protein | 0.573 | 0.025 |
| Ampicillin | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.357 | 0.327 |
| | Integron integrase IntI1 | 0.351 | 0.309 |
| | Class A beta-lactamase (EC 3.5.2.6) => CTX-M family, extended-spectrum | 0.340 | 0.309 |
| Ampicillin_Sulbactam | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.780 | 0.787 |
| | Class A beta-lactamase (EC 3.5.2.6) => CTX-M family, extended-spectrum | 0.772 | 0.764 |
| | Tryptophan synthase (indole-salvaging) (EC 4.2.1.122) | 0.752 | 0.774 |
| Aztreonam | Integron integrase IntI1 | 0.678 | 0.614 |
| | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.659 | 0.752 |
| | Tryptophan synthase (indole-salvaging) (EC 4.2.1.122) | 0.637 | 0.627 |
| Cefazolin | Class A beta-lactamase (EC 3.5.2.6) => CTX-M family, extended-spectrum | 0.676 | 0.667 |
| | Integron integrase IntI1 | 0.673 | 0.663 |
| | Tryptophan synthase (indole-salvaging) (EC 4.2.1.122) | 0.659 | 0.678 |
| Cefepime | Class A beta-lactamase (EC 3.5.2.6) => CTX-M family, extended-spectrum | 0.848 | 0.648 |
| | Tryptophan synthase (indole-salvaging) (EC 4.2.1.122) | 0.833 | 0.666 |
| | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.742 | 0.691 |
| Cefoxitin | Class A beta-lactamase (EC 3.5.2.6) => KPC family, carbapenem-hydrolyzing | 0.550 | 0.571 |
| | DUF3701 domain / Site-specific tyrosine recombinase | 0.502 | 0.561 |
| | H repeat-associated protein, YhhI family | 0.451 | 0.554 |
| Ceftazidime | Integron integrase IntI1 | 0.657 | 0.623 |
| | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.655 | 0.763 |
| | Tryptophan synthase (indole-salvaging) (EC 4.2.1.122) | 0.648 | 0.686 |
| Ceftriaxone | Class A beta-lactamase (EC 3.5.2.6) => CTX-M family, extended-spectrum | 0.823 | 0.700 |
| | Tryptophan synthase (indole-salvaging) (EC 4.2.1.122) | 0.802 | 0.714 |
| | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.769 | 0.797 |

| Antibiotic | PATRIC Function | PCC Actual MIC | PCC Predicted MIC |
|-------------------------|--|----------------|-------------------|
| Cefuroxime sodium | Aminoglycoside N(3)-acetyltransferase (EC 2.3.1.81) => AAC(3)-II,III,IV,VI,VIII,IX,X | 0.668 | 0.616 |
| | FIG00639751: hypothetical protein | 0.527 | -0.060 |
| | FIG00642442: hypothetical protein | 0.527 | -0.060 |
| Ciprofloxacin | Integron integrase IntI1 | 0.715 | 0.713 |
| | Tryptophan synthase (indole-salvaging) (EC 4.2.1.122) | 0.692 | 0.758 |
| | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.681 | 0.782 |
| Gentamicin | Aminoglycoside N(3)-acetyltransferase (EC 2.3.1.81) => AAC(3)-II,III,IV,VI,VIII,IX,X | 0.818 | 0.862 |
| | FIG00732118: hypothetical protein | 0.577 | 0.551 |
| | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.571 | 0.637 |
| Imipenem | Class A beta-lactamase (EC 3.5.2.6) => KPC family, carbapenem-hydrolyzing | 0.891 | 0.905 |
| | DUF3701 domain / Site-specific tyrosine recombinase | 0.828 | 0.865 |
| | H repeat-associated protein, YhhI family | 0.761 | 0.853 |
| Levofloxacin | probable bacteriophage protein STY1063 | 0.588 | 0.584 |
| | DNA helicase (EC 3.6.4.12), phage-associated | 0.568 | 0.602 |
| | colicin immunity protein | 0.557 | 0.571 |
| Meropenem | Class A beta-lactamase (EC 3.5.2.6) => KPC family, carbapenem-hydrolyzing | 0.923 | 0.814 |
| | DUF3701 domain / Site-specific tyrosine recombinase | 0.832 | 0.799 |
| | H repeat-associated protein, YhhI family | 0.733 | 0.818 |
| Nitrofurantoin | Integron integrase IntI1 | 0.433 | 0.507 |
| | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.423 | 0.491 |
| | TonB protein | 0.400 | 0.413 |
| Piperacillin_Tazobactam | plasmid stabilization system | 0.583 | 0.501 |
| | Class A beta-lactamase (EC 3.5.2.6) => TEM family | 0.581 | 0.662 |
| | probable bacteriophage protein STY1063 | 0.487 | 0.592 |
| Tetracycline | Tetracycline resistance regulatory protein TetR | 0.829 | 0.717 |
| | Tetracycline resistance, MFS efflux pump => Tet(A) | 0.628 | 0.851 |
| | Dihydropteroate synthase type-2 (EC 2.5.1.15) @ Sulfonamide resistance protein | 0.530 | 0.657 |

| Antibiotic | PATRIC Function | PCC Actual MIC | PCC Predicted MIC |
|-------------------------------|--|-------------------|----------------------|
| Tobramycin | Aminoglycoside N(6')-acetyltransferase (EC 2.3.1.82) => AAC(6')-Ib/AAC(6')-II | 0.837 | 0.853 |
| | Class D beta-lactamase (EC 3.5.2.6) => OXA-1 family | 0.685 | 0.704 |
| | Chloramphenicol O-acetyltransferase (EC 2.3.1.28) => CatB family | 0.654 | 0.703 |
| Trimethoprim_Sulfamethoxazole | Dihydropteroate synthase type-2 (EC 2.5.1.15) @ Sulfonamide resistance protein | 0.919 | 0.758 |
| | Integron integrase IntI1 | 0.796 | 0.784 |
| | Class A beta-lactamase (EC 3.5.2.6) => CTX-M family, extended-spectrum | 0.705 | 0.773 |

Table S5. The within ± 1 -tier accuracy of the XGBoost model built from whole genome contigs, AMR genes only, and non-AMR genes respectively.

| Antibiotic | Samples | Contigs Accuracy | 95% C.I. | AMR Genes Accuracy | 95% C.I. | Non-AMR Genes Accuracy | 95% C.I. |
|-------------------------------|---------|------------------|-----------|--------------------|-----------|------------------------|-----------|
| All | 32705 | 0.92 | 0.92,0.92 | 0.92 | 0.91,0.92 | 0.92 | 0.92,0.92 |
| Amikacin | 1667 | 0.97 | 0.96,0.98 | 0.96 | 0.95,0.97 | 0.97 | 0.97,0.98 |
| Ampicillin | 1666 | 1.00 | 0.99,1.00 | 1.00 | 0.99,1.00 | 1.00 | 0.99,1.00 |
| Ampicillin/Sulbactam | 1664 | 0.99 | 0.99,1.00 | 0.99 | 0.99,1.00 | 0.99 | 0.99,1.00 |
| Aztreonam | 1644 | 0.89 | 0.89,0.90 | 0.89 | 0.88,0.90 | 0.89 | 0.89,0.90 |
| Cefazolin | 1667 | 0.96 | 0.95,0.96 | 0.95 | 0.95,0.96 | 0.96 | 0.96,0.97 |
| Cefepime | 1571 | 0.61 | 0.58,0.64 | 0.61 | 0.58,0.63 | 0.60 | 0.58,0.63 |
| Cefoxitin | 1645 | 0.90 | 0.89,0.91 | 0.89 | 0.87,0.90 | 0.90 | 0.89,0.92 |
| Ceftazidime | 1667 | 0.92 | 0.91,0.93 | 0.91 | 0.91,0.92 | 0.91 | 0.90,0.92 |
| Ceftriaxone | 1667 | 0.89 | 0.87,0.90 | 0.90 | 0.89,0.91 | 0.89 | 0.88,0.91 |
| Cefuroxime sodium | 1575 | 0.99 | 0.99,1.00 | 0.99 | 0.99,1.00 | 0.99 | 0.99,1.00 |
| Ciprofloxacin | 1664 | 0.98 | 0.97,0.98 | 0.98 | 0.97,0.98 | 0.97 | 0.97,0.98 |
| Gentamicin | 1667 | 0.95 | 0.93,0.96 | 0.96 | 0.95,0.96 | 0.95 | 0.94,0.96 |
| Imipenem | 1666 | 0.94 | 0.93,0.95 | 0.92 | 0.91,0.93 | 0.94 | 0.93,0.95 |
| Levofloxacin | 1666 | 0.97 | 0.96,0.97 | 0.97 | 0.96,0.98 | 0.96 | 0.95,0.97 |
| Meropenem | 1660 | 0.93 | 0.91,0.95 | 0.91 | 0.89,0.92 | 0.93 | 0.92,0.94 |
| Nitrofurantoin | 895 | 0.96 | 0.95,0.97 | 0.96 | 0.95,0.96 | 0.96 | 0.96,0.97 |
| Piperacillin/Tazobactam | 1662 | 0.78 | 0.77,0.79 | 0.77 | 0.75,0.80 | 0.77 | 0.76,0.79 |
| Tetracycline | 1667 | 0.89 | 0.87,0.90 | 0.90 | 0.89,0.92 | 0.89 | 0.88,0.90 |
| Tobramycin | 1666 | 0.95 | 0.94,0.96 | 0.95 | 0.94,0.96 | 0.93 | 0.92,0.95 |
| Trimethoprim/Sulfamethoxazole | 1667 | 0.95 | 0.94,0.96 | 0.94 | 0.93,0.95 | 0.95 | 0.93,0.96 |

Table S6. The number of different MIC values observed within the top five *K. pneumoniae* MLST types in the dataset.

| Antibiotic | MLST type | | | | |
|-------------------------------|----------------------|----------------------|--------------------|--------------------|---------------------|
| | 307 (560 genomes) | 258 (404 genomes) | 16 (86 genomes) | 15 (56 genomes) | 280 (27 genomes) |
| Amikacin | 5 | 6 | 3 | 4 | 2 |
| Ampicillin | 1 | 1 | 1 | 1 | 1 |
| Ampicillin/Sulbactam | 2 | 3 | 3 | 2 | 1 |
| Aztreonam | 5 | 5 | 5 | 4 | 2 |
| Cefazolin | 2 | 3 | 2 | 4 | 1 |
| Cefepime | 6 | 8 | 6 | 6 | 3 |
| Cefoxitin | 4 | 4 | 4 | 4 | 4 |
| Ceftazidime | 5 | 3 | 4 | 5 | 3 |
| Ceftriaxone | 3 | 6 | 3 | 3 | 1 |
| Cefuroxime sodium | 1 | 2 | 2 | 2 | 1 |
| Ciprofloxacin | 1 | 1 | 1 | 1 | 2 |
| Gentamicin | 6 | 6 | 5 | 4 | 1 |
| Imipenem | 8 | 6 | 3 | 6 | 1 |
| Levofloxacin | 3 | 2 | 2 | 2 | 3 |
| Meropenem | 7 | 10 | 4 | 3 | 1 |
| Nitrofurantoin | 4 | 1 | 3 | 4 | 3 |
| Piperacillin/Tazobactam | 7 | 7 | 7 | 7 | 5 |
| Tetracycline | 5 | 6 | 4 | 5 | 1 |
| Tobramycin | 7 | 5 | 4 | 4 | 2 |
| Trimethoprim/Sulfamethoxazole | 5 | 5 | 3 | 4 | 1 |


Table S7. The occurrence of AMR functions within the *K. pneumoniae* genomes. The column numbers correspond to the columns of the heatmap in in Figure S3 and the counts are the number of genomes with that AMR function.

| Column | Count | Function |
|--------|-------|---|
| 1 | 4 | Class A beta-lactamase (EC 3.5.2.6) |
| 2 | 12 | Class A beta-lactamase (EC 3.5.2.6) => CARB/PSE family, carbenicillin-hydrolyzing |
| 3 | 1046 | Class A beta-lactamase (EC 3.5.2.6) => CTX-M family, extended-spectrum |
| 4 | 3 | Class A beta-lactamase (EC 3.5.2.6) => GES family |
| 5 | 493 | Class A beta-lactamase (EC 3.5.2.6) => KPC family, carbapenem-hydrolyzing |
| 6 | 38 | Class A beta-lactamase (EC 3.5.2.6) => LAP family |
| 7 | 14 | Class A beta-lactamase (EC 3.5.2.6) => LEN family |
| 8 | 4 | Class A beta-lactamase (EC 3.5.2.6) => OKP-A family, broad-spectrum |
| 9 | 10 | Class A beta-lactamase (EC 3.5.2.6) => OKP-B family, broad-spectrum |
| 10 | 1 | Class A beta-lactamase (EC 3.5.2.6) => SCO family |
| 11 | 1646 | Class A beta-lactamase (EC 3.5.2.6) => SHV family |
| 12 | 802 | Class A beta-lactamase (EC 3.5.2.6) => TEM family |
| 13 | 1 | Class C beta-lactamase (EC 3.5.2.6) |
| 14 | 2 | Class C beta-lactamase (EC 3.5.2.6) => ADC family |
| 15 | 2 | Class C beta-lactamase (EC 3.5.2.6) => BlaEC family |
| 16 | 2 | Class C beta-lactamase (EC 3.5.2.6) => DHA/MOR family |
| 17 | 10 | Class C beta-lactamase (EC 3.5.2.6) => FOX family, cephalosporin-hydrolyzing |
| 18 | 23 | Class D beta-lactamase (EC 3.5.2.6) |
| 19 | 383 | Class D beta-lactamase (EC 3.5.2.6) => OXA-1 family |
| 20 | 6 | Class D beta-lactamase (EC 3.5.2.6) => OXA-2 family |
| 21 | 2 | Class D beta-lactamase (EC 3.5.2.6) => OXA-24 family, carbapenem-hydrolyzing |
| 22 | 8 | Class D beta-lactamase (EC 3.5.2.6) => OXA-48 family, some variants carbapenem-hydrolyzing |
| 23 | 2 | Class D beta-lactamase (EC 3.5.2.6) => OXA-51 family, carbapenem-hydrolyzing |
| 24 | 11 | Subclass B1 beta-lactamase (EC 3.5.2.6) => NDM family |
| 25 | 47 | Aminoglycoside 2''-nucleotidyltransferase (EC 2.7.7.46) => APH(2'')-Ia (AadB family) |
| 26 | 669 | Aminoglycoside 3''-nucleotidyltransferase (EC 2.7.7.-) => APH(3'')-Ia (AadA family) |
| 27 | 2 | Aminoglycoside 3''-nucleotidyltransferase, putative |
| 28 | 531 | Aminoglycoside 3''-phosphotransferase (EC 2.7.1.87) => APH(3'')-I |
| 29 | 345 | Aminoglycoside 3'-phosphotransferase (EC 2.7.1.95) => APH(3')-I |
| 30 | 48 | Aminoglycoside 3'-phosphotransferase (EC 2.7.1.95) => APH(3')-II/APH(3')-XV |
| 31 | 8 | Aminoglycoside 3'-phosphotransferase (EC 2.7.1.95) => APH(3')-III/APH(3')-IV/APH(3')-VI/APH(3')-VII |
| 32 | 31 | Aminoglycoside 4-phosphotransferase (EC 2.7.1.-) => APH(4)-I |
| 33 | 535 | Aminoglycoside 6-phosphotransferase (EC 2.7.1.72) => APH(6)-Ic/APH(6)-Id |
| 34 | 1 | Aminoglycoside 6-phosphotransferase, putative |
| 35 | 646 | Aminoglycoside N(3)-acetyltransferase (EC 2.3.1.81) => AAC(3)-II,III,IV,VI,VIII,IX,X |

| Column | Count | Function |
|--------|-------|--|
| 36 | 3 | Aminoglycoside N(6')-acetyltransferase (EC 2.3.1.82) => AAC(6')-Ia (and related AACs) |
| 37 | 707 | Aminoglycoside N(6')-acetyltransferase (EC 2.3.1.82) => AAC(6')-Ib/AAC(6')-II |
| 38 | 1665 | Aminoglycosides efflux system AcrAD-TolC, inner-membrane proton/drug antiporter AcrD (RND type) |
| 39 | 369 | Tetracycline resistance, MFS efflux pump => Tet(A) |
| 40 | 5 | Tetracycline resistance, MFS efflux pump => Tet(B) |
| 41 | 328 | Tetracycline resistance, MFS efflux pump => Tet(D) |
| 42 | 3 | Tetracycline resistance, MFS efflux pump => Tet(J) |
| 43 | 2 | Tetracycline resistance, ribosomal protection type => Tet(M) |
| 44 | 1 | Tetracycline resistance, ribosomal protection type => Tet(W) |
| 45 | 487 | Macrolide 2'-phosphotransferase => Mph(A) family |
| 46 | 20 | Macrolide 2'-phosphotransferase => Mph(E)/Mph(G) family |
| 47 | 1666 | Macrolide export ATP-binding/permease protein MacB |
| 48 | 17 | Macrolide resistance, MFS efflux pump => Mef(B) |
| 49 | 1666 | Macrolide-specific efflux protein MacA |
| 50 | 322 | Chloramphenicol O-acetyltransferase (EC 2.3.1.28) => CatA1/CatA4 family |
| 51 | 217 | Chloramphenicol O-acetyltransferase (EC 2.3.1.28) => CatA2 family |
| 52 | 388 | Chloramphenicol O-acetyltransferase (EC 2.3.1.28) => CatB family |
| 53 | 56 | Chloramphenicol resistance, MFS efflux pump => CmlA family |
| 54 | 20 | Chloramphenicol/florfenicol resistance, MFS efflux pump => FloR family |
| 55 | 1663 | AcrZ membrane protein associated with AcrAB-TolC multidrug efflux pump |
| 56 | 1666 | Multidrug efflux system AcrAB-TolC, inner-membrane proton/drug antiporter AcrB (RND type) |
| 57 | 1666 | Multidrug efflux system AcrAB-TolC, membrane fusion component AcrA |
| 58 | 1666 | Multidrug efflux system AcrEF-TolC, inner-membrane proton/drug antiporter AcrF (RND type) |
| 59 | 1666 | Multidrug efflux system AcrEF-TolC, membrane fusion component AcrE |
| 60 | 1663 | Multidrug efflux system EmrAB-OMF, inner-membrane proton/drug antiporter EmrB (MFS type) |
| 61 | 1663 | Multidrug efflux system EmrAB-OMF, membrane fusion component EmrA |
| 62 | 13 | Multidrug efflux system EmrKY-TolC, inner-membrane proton/drug antiporter EmrY (MFS type) |
| 63 | 4 | Multidrug efflux system EmrKY-TolC, membrane fusion component EmrK |
| 64 | 1665 | Multidrug efflux system MdtABC-TolC, inner-membrane proton/drug antiporter MdtB (RND type) |
| 65 | 1665 | Multidrug efflux system MdtABC-TolC, inner-membrane proton/drug antiporter MdtC (RND type) |
| 66 | 1665 | Multidrug efflux system MdtABC-TolC, membrane fusion component MdtA |
| 67 | 4 | Multidrug efflux system MdtEF-TolC, inner-membrane proton/drug antiporter MdtF (RND type) |
| 68 | 4 | Multidrug efflux system MdtEF-TolC, membrane fusion component MdtE |
| 69 | 2 | Multidrug efflux system, inner membrane proton/drug antiporter (RND type) => MexB of MexAB-OprM |
| 70 | 1 | Multidrug efflux system, inner membrane proton/drug antiporter (RND type) => MexD of MexCD-OprJ system |

| Column | Count | Function |
|--------|-------|--|
| 71 | 5 | Multidrug efflux system, inner membrane proton/drug antiporter (RND type) => MexI of MexHI-OpmD system |
| 72 | 6 | Multidrug efflux system, inner membrane proton/drug antiporter (RND type) => MexQ of MexPQ-OpmE system |
| 73 | 1 | Multidrug efflux system, membrane fusion component => MexC of MexCD-OprJ system |
| 74 | 3 | Multidrug efflux system, membrane fusion component => MexH of MexHI-OpmD system |
| 75 | 6 | Multidrug efflux system, membrane fusion component => MexP of MexPQ-OpmE system |
| 76 | 1 | Multidrug efflux system, outer membrane factor lipoprotein => OprJ of MexCD-OprJ system |
| 77 | 3 | Multidrug efflux system, outer membrane factor lipoprotein of OprM/OprM family |
| 78 | 4 | Outer membrane factor (OMF) lipoprotein associated wth EmrAB-OMF efflux system |
| 79 | 7 | 23S rRNA (adenine(2058)-N(6))-dimethyltransferase (EC 2.1.1.184) => Erm(B) |
| 80 | 2 | 3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35), FabG4 |
| 81 | 20 | ABC-F type ribosomal protection protein => Msr(E) |
| 82 | 1667 | Carbohydrate-selective porin OprB |
| 83 | 1657 | Catalase-peroxidase KatG (EC 1.11.1.21) |
| 84 | 13 | Erythromycin esterase (EC 3.1.1.-) => EreA family |
| 85 | 1666 | Hydrogen peroxide-inducible genes activator => OxyR |
| 86 | 1660 | Multidrug resistance regulator EmrR (MprA) |
| 87 | 1665 | Multidrug resistance transporter => Bicyclomycin resistance protein Bcr |
| 88 | 1660 | Multiple antibiotic resistance protein MarA |
| 89 | 1659 | Multiple antibiotic resistance protein MarB |
| 90 | 1660 | Multiple antibiotic resistance protein MarR |
| 91 | 1667 | Outer membrane channel TolC (OpmH) |
| 92 | 3 | Outer membrane low permeability porin, OprD family |
| 93 | 1 | Outer membrane low permeability porin, OprD family => OccD2/OpdC |
| 94 | 1664 | Outer membrane low permeability porin, OprD family => OccD6/OprQ involved in adhesion |
| 95 | 1 | Pellicle/biofilm biosynthesis inner membrane protein PslK, MATE transporter family |
| 96 | 1 | Pellicle/biofilm biosynthesis protein PslA, polyprenyl glycosylphosphotransferase |
| 97 | 78 | Pentapeptide repeat protein QnrB family |
| 98 | 281 | Pentapeptide repeat protein QnrB family => Quinolone resistance protein QnrB10 |
| 99 | 2 | Probable (3R)-hydroxyacyl-CoA dehydratase HtdX |
| 100 | 3 | Transcriptional activator GadE |
| 101 | 1665 | Transcriptional regulator of acrAB operon, AcrR |
| 102 | 1 | Two component system sensor histidine kinase MtrB |

(a)



(b)




Figure S1. Results of the 2^k factorial design on the XGBoost model. **(a)** Three dimensional plot showing the relationship between maximum depth, column subsampling and row subsampling parameters. The size of the spheres represent the within 1-tier accuracy score for the given model. Larger spheres indicate higher accuracy. Dashed lines are added to aid in visualization. The image shows that maximum tree depth plays the largest role in the XGBoost model with column and row subsampling having smaller roles. **(b)** Heat map showing the relationship between learning rate and maximum tree depth. In the color scheme, white is most accurate and dark blue and green are least accurate. The image shows that lower depth and learning rates produce more accurate models.




Figure S2. Heat maps comparing the accuracies of the XGBoost model for individual MICs generated from (A) AMR genes, (B) Non-AMR genes, and (C) full contigs. The X-axis of the heatmap shows the actual MIC ($\mu\text{g/ml}$) for a bin and the Y-axis lists the antibiotics. The within ± 1 -tier accuracy of a particular antibiotic-MIC bin is denoted by color, with red and orange being least accurate and bright yellow and green being most accurate. The number within each cell represents the number of samples (genomes with the MIC) within the bin. The data depict genomes for which there is at least one AMR gene called by PATRIC or CARD.




Figure S3. A phylogenetic tree of *K. pneumoniae* isolates used in this study and the distribution of AMR genes within each genome. The tree is based on a concatenated alignment of the MLST protein encoding genes and is rooted on *E. coli* K-12 substr. MG1655 (K12). Genomes belonging to MLST 307 and 258 are colored green and blue respectively. 409 of the original 1668 genomes with differing sets of AMR genes are shown. Each column in the heatmap depicts the absence (gray cells) or presence (cells with other colors) of genes with AMR functions based on either PATRIC or CARD. Columns 1-24 represent genes with functions relating to beta-lactam resistance (bright green), columns 25-38 represent genes with functions relating to aminoglycoside resistance (green), columns 39-44 represent genes with functions relating to tetracycline resistance (dark green), columns 45-49 represent genes with functions relating to macrolide resistance (blue green), columns 50-54 represent genes with functions relating to chloramphenicol resistance (gray-blue), columns 55-78 represent genes with functions relating to efflux mechanisms (blue), and columns 79-102 represent genes with other AMR-related functions (bright blue). The functions for each column of the heat map are shown in Table S7. Strain names with the prefix KPN were described previously³, numbered strains are new to this study.